×
Back to Agenda
Industry Trends, Successes, and Failures in Orphan and Rare Disease Therapeutics
Session Chair(s)
Christine Blazynski, PHD
Chief Science Officer and Senior Vice President, Citeline, Inc., United States
This forum will overview orphan and rare disease drug development from the patient and affected community perspective to the industry's response over the past 30 years until today. The activist community will be contrasted with how industry has approached the needs of the few.
Learning Objective : Evaluate industry's successes and failures in developing drugs that address rare and orphan diseases; Discuss failed and/or abandoned efforts in this therapeutic area; Report on current development pipeline and high interest versus low interest diseases.
Speaker(s)
Robin Winter-Sperry, MD
Global Medical Affairs , Scientific Resilience, United States
When Your Company Adopts an Orphan Drug
Christine Blazynski, PHD
Chief Science Officer and Senior Vice President, Citeline, Inc., United States
Industry Trends, Successes and Failures in Orphan and Rare Disease Therapeutics
Have an account?